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behalf of the Gen-C study group
Abstract 
Background and purpose: Contradictory data exist on the association between host interleukin-28B (IL28B) 
rs12979860 genotype and liver fibrosis in patients with chronic hepatitis C (CHC). This large, international, obser-
vational study (NCT01675427/MV25600) investigated relationships between IL28B rs12979860 genotype and liver 
fibrosis stage in CHC patients.
Methods: A total of 3003 adult, treatment-naive CHC patients were enrolled into the study. Patients made one study 
visit to provide a blood sample for genotyping; other data were obtained from medical records.
Results: 2916 patients comprised the analysis population; the majority were enrolled in Europe (n = 2119), were 
Caucasian (n = 2582) and had hepatitis C virus (HCV) genotype (G)1 infection (n = 1702) (G2 = 323, G3 = 574, 
G4 = 260). Distribution of IL28B genotypes varied according to region of enrolment, patient ethnicity and HCV 
genotype. A significant association was observed between increasing number of IL28B T alleles and the prevalence 
of cirrhosis/transition to cirrhosis (based on biopsy or non-invasive assessments) in G1-infected patients (CC = 22.2% 
[111/499], CT = 27.5% [255/928], TT = 32.3% [87/269]; p = 0.0018). The association was significant in the large sub-
group of European Caucasian G1 patients (n = 1245) but not in the smaller Asian (n = 25), Latin American (n = 137) 
or Middle Eastern (n = 289) G1 subgroups. IL28B genotype was not associated with liver fibrosis stage in patients with 
HCV G2, G3 or G4 infection.
Conclusion: This large, international study found that IL28B rs12979860 genotype is significantly associated with liver 
fibrosis stage in CHC patients with HCV G1 infection. This association was evident in European Caucasians but not in 
G1-infected patients from Asia, Latin America or the Middle East.
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Background
Host interleukin-28B (IL28B) genotype is associated with 
spontaneous clearance of acute hepatitis C virus (HCV) 
infection, response to interferon (IFN)-based treat-
ment, and with the development of hepatocellular carci-
noma (HCC) in patients with chronic hepatitis C (CHC) 
(Thomas et  al. 2009; Ge et  al. 2009; Zhang et  al. 2016). 
Genome-wide association studies have identified single-
nucleotide polymorphisms (SNPs) in close proximity to 
the IL28B gene that encode for IFN lambda (IFN-λ), with 
strong associations with spontaneous or IFN-induced 
clearance of HCV (Thomas et  al. 2009; Ge et  al. 2009; 
Rauch et al. 2010; Suppiah et al. 2009; Tanaka et al. 2009). 
In particular, a host IL28B rs12979860 CC genotype is 
associated with the highest, and TT genotype the low-
est, rates of response to IFN-based therapy (Thomas et al. 
2009; Ge et  al. 2009; Mangia et  al. 2010; Asselah et  al. 
2012; De Nicola et al. 2012; Poordad et al. 2012; Lawitz 
et al. 2013; Susser et al. 2014). The T allele also increases 
the risk of HCC associated with HCV (Zhang et al. 2016). 
In addition, differences in the distribution of IL28B geno-
types explain, in part, historical observations of low sus-
tained virological response (SVR) rates in Black or Latino 
patients and high SVR rates in Asian patients (Muir et al. 
2004; Yu et al. 2008; Rodriguez-Torres et al. 2009).
Despite the established role of host IL28B genotype as a 
predictor of response to therapy, the association between 
IL28B polymorphisms and the natural history of HCV 
is currently the subject of debate. CHC patients with an 
IL28B CC genotype had higher alanine transaminase 
(ALT) levels and greater hepatic necro-inflammatory 
activity at baseline, with worse clinical outcomes over 
4  years of follow-up than patients with non-CC geno-
types (Noureddin et  al. 2013). However, the same study 
observed no difference in the rate of fibrosis progression 
between patients with CC and non-CC genotypes. Other 
studies have yielded contradictory results on the asso-
ciation between IL28B genotype and fibrosis progression 
(Asselah et al. 2012; Falleti et al. 2011; Fabris et al. 2011; 
Marabita et  al. 2011; Di Marco et  al. 2012; D’Ambrosio 
et al. 2014).
While the efficacy of recently introduced, IFN-free 
treatment regimens is not affected by host IL28B geno-
type, their use is limited to patients with advanced fibro-
sis in many jurisdictions (Lawitz et  al. 2013; Jacobson 
et al. 2013). Therefore, predictors of fibrosis progression 
may provide a valuable tool for selection of patients eli-
gible for treatment. In addition, dual peginterferon alfa/
ribavirin therapy and protease inhibitor-based triple 
therapy continue to be used in many regions (Pawlotsky 
2014). Given that advanced fibrosis is associated with 
lower rates of SVR to IFN-based therapies, the identifi-
cation factors predictive of fibrosis stage has implications 
for treatment selection and optimization (Poordad et al. 
2012; Lawitz et al. 2013; Hadziyannis et al. 2004; Bonnet 
et al. 2014; Manns et al. 2014; Jacobson et al. 2014).
The primary objective of the Gen-C study was to inves-
tigate associations between IL28B genotype and fibrosis 
stage in CHC patients, in addition to gathering further 
information on the distribution of IL28B genotypes by 
HCV genotype, geographic region and ethnicity. The 
final results from treatment-naive patients are reported 
here.
Methods
Patients and study design
Gen-C is a large, international, observational study 
of adults with CHC (clinicaltrials.gov, trial identifier 
NCT01675427). Patients were excluded if they had hepa-
titis B virus co-infection, a history of decompensated liver 
disease, major organ transplantation or end-stage renal 
disease. Only treatment-naive patients were included in 
the present analysis. Enrolment was at the discretion of 
the investigator.
The primary objective of the Gen-C study was to inves-
tigate the relationship between IL28B genotypes and liver 
fibrosis stage in patients with CHC.
Secondary objectives included relationships between 
IL28B genotypes and liver inflammation, ALT levels and 
patient demographics, and the distribution of IL28B 
genotypes by HCV genotype, geographic region and 
ethnicity.
Data collection
Patients who provided written, informed consent made 
one study visit for blood sample collection, which was 
analysed in a central laboratory in Germany or Italy.
A 5 ml sample of whole blood was collected in a tube 
containing ethylenediaminetetraacetic acid. After collec-
tion, the tube was gently inverted 10 times and was not to 
be centrifuged. A bar-coded label was then applied to the 
tube and the sample was stored at −20  °C before being 
packed in dry ice and shipped by courier to the central 
laboratory. Samples were stored at −20  °C until DNA 
extraction then were thawed overnight (i.e., for approxi-
mately 16 h) and rolled for approximately 30 min before 
opening.
Standard polymerase chain reaction technology was 
used to genotype SNPs near IL28B (rs12979860 [CC, 
TC and TT] and rs8099917 [TT, GT or GG]) and ino-
sine triphosphate pyrophosphatase (ITPA) (rs1127354 
[AA, CA or CC] and rs7270101 [CC, AC or AA]). Posi-
tive controls for IL28B rs12979860 TC and rs8099917 TG 
were obtained from TIB MOLBIOL GmbH, Berlin, Ger-
many. Nucleic acid purification was performed using the 
MagNa Pure 96 System (Roche Diagnostics, Mannheim, 
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Germany). Genomic DNA was extracted from a 50  µL 
sample by adding MagNa Pure96 to make up an eluate 
of 100  µL. Genotype was then determined by commer-
cial genotyping assays (LightMix Kit rs12979860 IL28B, 
LightSNiP rs8099917 IL28B, LightSNiP rs7270101 ITPA, 
LightSNiP rs1127354 ITPA; Roche Diagnostics, GmbH) 
using an eluate of 5 µL.
The results of previous invasive or non-invasive fibrosis 
assessments were entered in the electronic Case Report 
Form. Investigators recorded the date, type (invasive or 
non-invasive) and result of the assessment. Fibrosis stage 
was documented categorically (Cirrhosis, Transition to 
cirrhosis, Advanced fibrosis-non-cirrhotic, Mild/mini-
mal fibrosis, No fibrosis). Cirrhosis/transition to cirrhosis 
was defined by biopsy (Ishak 4–6, METAVIR 3–4, Batts 
and Ludwig 3–4, Knodell 3–4 or Scheuer 3–4) or non-
invasive assessment.
Statistical analyses
Enrolment of 1500 treatment-naive and 1500 treatment-
experienced patients with evaluable data was estimated 
to provide 80% power for a Chi square test to detect an 
association between liver fibrosis stage (five degrees of 
freedom) and IL28B genotype (three degrees of freedom) 
at a significance level of 0.05. The final enrolment target 
of 4000–6000 patients was arrived at after allowing for 
patient dropout and patients without evaluable data.
The analysis population was defined as all patients 
with blood samples and available data for IL28B SNPs. 
For analysis of the primary endpoint, patients were 
categorized as having cirrhosis/transition to cirrho-
sis or no cirrhosis. The relationship between cirrhosis 
status (cirrhosis/transition to cirrhosis vs no cirrhosis) 
and number of rs12979860 IL28B T alleles was inves-
tigated by Cochran-Armitage trend test. The relation-
ship between IL28B genotype and all other fibrosis 
measurements (e.g. METAVIR fibrosis stage) was inves-
tigated using the Jonckheere-Terpstra trend test. The 
same methods were used to investigate the relationship 
between IL28B and other continuous, ordinal or binary 
variables, while the Pearson Chi square test was used to 
compare the association between IL28B genotypes and 
nominal variables.
Relationships between baseline characteristics and 
cirrhosis status were explored by multivariate logistic 
regression (MLR) analysis. Variables considered in the 
analysis were: alcohol consumption, ALT ratio, aspar-
tate transaminase (AST) ratio, age, autoimmune disease, 
body mass index (BMI), body weight, ethnic origin, glu-
cose intolerance/diabetes, HCV genotype, HCV RNA 
level, HIV–HCV co-infection, liver disease other than 
CHC, platelets, region of enrolment and years since HCV 
infection.
Results
A total of 3003 treatment-naive patients were enrolled 
at 213 centres across 30 countries between August 2011 
(first patient) and September 2013 (last patient last visit) 
(Fig. 1). Overall, 87 patients were excluded, and therefore 
the analysis population comprised 2916 patients.
Among the total population of 2916 patients, a fibrosis 
assessment was conducted in 2902 individuals (99.5%), 
of whom 26.1% were diagnosed with cirrhosis/transition 
to cirrhosis (Table 1). The majority of patients were male, 
Caucasian and had HCV G1 infection, with similar char-
acteristics across IL28B rs12979860 genotypes (Table 1). 
More patients with CC or CT compared with TT geno-
types had a high viral load and elevated ALT levels. The 
distribution of HCV genotypes varied by region (Fig. 2).
IL28B genotype and liver fibrosis stage
Among HCV G1-infected patients, the prevalence of cir-
rhosis/transition to cirrhosis increased with the number 
of rs12979860 T alleles overall (p = 0.0018) (Fig. 3a), in 
Caucasians (p = 0.0010) (Fig. 3b) and in European Cau-
casians (p = 0.0023) (Fig. 3c).
No statistically significant associations were observed 
for other HCV genotypes. Among HCV G1 patients 
enrolled at European study sites (n = 1245), an associa-
tion was observed between the prevalence of cirrhosis/
transition to cirrhosis and the number of rs12979860 T 
alleles (p = 0.0030, Table 2). For patients enrolled in Asia, 
Latin America or the Middle East, no significant associa-
tions were observed (Table 2; Additional file 1: Tables S1–
S4). However, these results should be interpreted with 
caution due to low patient numbers.
MLR analyses
Older age, higher BMI, HCV G1 infection (vs G2), 
higher AST ratio, lower platelet count, enrolment at an 
Asian/Middle Eastern site (vs European), liver disease 
other than CHC and glucose intolerance/diabetes were 
significantly associated with an increased risk of cir-
rhosis/transition to cirrhosis (Fig.  4a). IL28B genotype 
was not associated with cirrhosis/transition to cirrho-
sis in the final MLR model. In contrast, when only HCV 
G1-infected patients were considered, rs12979860 geno-
type (CT or TT vs CC) was significantly associated with 
cirrhosis/transition to cirrhosis (Fig. 4b). When the anal-
ysis was further restricted to European HCV G1 patients, 
rs8099917 GG and TG genotype (vs TT) was significantly 
associated with cirrhosis/transition to cirrhosis (Fig. 4c).
IL28B rs12979860 genotype, serum ALT levels 
and necro‑inflammatory grade
A statistically significant decrease in mean ALT ratio 
was observed with an increasing number of rs12979860 
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T alleles for G1 (p =  0.0007), G2 (p =  0.0061) and G3 
(p  <  0.0001) but not G4 patients (Additional file  1: 
Table S5).
No association was observed between IL28B geno-
type and METAVIR fibrosis stage or necro-inflammatory 
grade (Additional file 1: Tables S6 and S7), or liver stiff-
ness (Additional file 1: Table S8) overall or when stratified 
by HCV genotype. There was however significant asso-
ciation between IL28B genotype and AST to platelet ratio 
index (APRI) score and Fibrosis-4 (FIB-4) score (age, 
AST, platelet count and ALT) in the overall population 
and in the subgroup of patients with G2 and G3 infection 
(Additional file 1: Tables S9 and S10).
rs12979860 genotype distributions
In general, an rs12979860 CT genotype was more com-
mon than a CC or TT genotype (Fig. 5a) and there was a 
significant association between HCV genotype and IL28B 
genotype (p  <  0.0001), with the CC genotype occurring 
more frequently in G2 and G3 patients than in G1 and 
G4 patients.
rs12979860 genotype was significantly associ-
ated with region of enrolment overall (p  <  0.0001, 
Fig.  5b) and in HCV G1 and G4 patients [p  <  0.0001 
and p  =  0.0467, respectively (Table  3)]. rs12979860 
distribution was not, however, homogenous across 
the countries within each region (Additional file  1: 
Table S8).
rs12979860 genotype was significantly associated with 
patient ethnic origin (p < 0.0001); CC was the most com-
mon genotype in Asian patients, but was infrequent in 
Black patients (Fig. 5c).
Discussion
The primary finding of the Gen-C study was a positive 
association between an increasing number of rs12979860 
T alleles and the prevalence of cirrhosis/transition to cir-
rhosis in treatment-naïve G1 patients. While the positive 
association between T allele and fibrosis stage observed 
for HCV G1 broadly supports findings from several pre-
vious studies, it should be taken into account that these 
studies did not differentiate between HCV genotypes, 
Patients enrolled
n = 4766
•   Asia (n = 154; 5.1%): Pakistan, Taiwan 
•   Europe (n = 2184; 72.7%): Belgium, Estonia, France, Germany, Greece, Italy (n = 831; 27.1%), Latvia, Lithuania, Macedonia, 
Portugal, Romania, Serbia, Slovakia, Sweden, Switzerland
•   Latin America (n = 166; 5.5%): Argentina, Chile, Mexico, Peru, Venezuela
Middle East (n = 499; 16.6%): Egypt, Kuwait, Lebanon, Oman, Qatar, Syria, Turkey, UAE
Patients in analysis population
n = 2916
Patients excluded from analysis populationa
n = 87
• Rejection of informed consent after initial enrollment; n = 1 
• Age <18 years or missing; n = 2
• No sample taken; n = 25
• No IL28B data; n = 45
• No CHC; n = 7
• History or evidence of decompensated liver disease or 
information missing; n = 4
• End stage renal disease or information missing; n = 1 
• Co-infection with hepatitis B; n = 2
• History of major organ transplantation; n = 2
Treatment-naive patients 
n = 3003
Treatment-experienced patients 
n = 1763
•
Fig. 1 Patient flow diagram. aPatients may have been excluded for more than one reason
Page 5 of 13Mangia et al. SpringerPlus  (2016) 5:1990 
Table 1 Patient demographics and background disease characteristics
IL28B rs12979860 genotype
CC (n = 978) CT (n = 1518) TT (n = 420) P valuee
Mean age, years ± SD 46.8 ± 13.6 47.3 ± 13.2 46.8 ± 12.6 0.6973e
 G1 (n = 1702) 47.9 ± 13.3 48.5 ± 13.2 48.1 ± 12.2 0.6602e
 G2 (n = 323) 54.7 ± 13.1 55.1 ± 12.6 51.1 ± 15.9 0.5182e
 G3 (n = 574) 39.2 ± 9.8 39.6 ± 10.3 39.0 ± 9.4 0.6864e
 G4 (n = 260) 45.5 ± 13.2 44.3 ± 10.2 46.0 ± 10.4 0.7789e
Male, n (%) 582 (59.5) 802 (52.8) 224 (53.3) 0.0049f
Ethnic origin, n (%) <0.0001g
 Asian 89 (9.1) 83 (5.5) 9 (2.1)
 Black 5 (0.5) 24 (1.6) 19 (4.5)
 Caucasian 860 (87.9) 1349 (88.9) 373 (88.8)
 Othera 24 (2.5) 62 (4.1) 19 (4.5)
Region, n (%) <0.0001g
 Asia 78 (8.0) 66 (4.3) 8 (1.9)
 Europe 721 (73.7) 1095 (72.1) 303 (72.1)
 Middle East 138 (14.1) 272 (17.9) 75 (17.9)
 Latin America 41 (4.2) 85 (5.6) 34 (8.1)
BMI, kg/m2, mean ± SD 25.8 ± 4.4 26.0 ± 4.5 26.0 ± 4.7 0.2617e
HCV genotype, n (%) <0.0001g
 Known genotype 957 (97.9) 1501 (98.9) 414 (98.6)
 G1b 500 (52.2) 930 (62.0) 272 (65.7)
 G2b 126 (13.2) 160 (10.7) 37 (8.9)
 G3b 232 (24.2) 277 (18.5) 65 (15.7)
 G4b 92 (9.6) 129 (8.6) 39 (9.4)
 G5/6b 7 (0.7) 5 (0.3) 1 (0.2)
Unknown/missing 21 (2.1) 17 (1.1) 6 (1.4)
Duration of HCV infection, mean years ± SD 14.0 ± 12.3 14.0 ± 12.6 13.0 ± 12.4 0.1860e
 G1 (n = 1615) 14.8 ± 13.1 14.5 ± 13.0 12.7 ± 12.5 0.0536e
 G2 (n = 303) 16.6 ± 12.9 15.9 ± 13.5 16.6 ± 15.8 0.5129e
 G3 (n = 552) 10.9 ± 9.6 11.8 ± 10.7 11.3 ± 8.5 0.4443e
 G4 (n = 249) 13.7 ± 10.6 13.1 ± 10.4 14.8 ± 13.8 0.9733e
HIV–HCV co-infection, n (%) 38 (3.9) 49 (3.2) 15 (3.6) 0.6000f
Autoimmune disease, n (%) 23 (2.4) 46 (3.0) 6 (1.4) 0.6433f
Liver disease other than CHC, n (%) 34 (3.5) 35 (2.3) 13 (3.1) 0.3728f
Glucose intolerance/diabetes, n (%) 73 (7.5) 125 (8.2) 33 (7.9) 0.6614f
Alcohol consumption, mean units/week ± SD 1.83 ± 8.7 1.10 ± 5.2 0.87 ± 3.5 0.1423e
Previous/current drug use/methadone or substitute therapy, n (%) 289 (29.6) 361 (23.8) 96 (22.9) 0.0013f
Smoking, n (%)b 0.0070g
 Never 496 (50.9) 887 (58.5) 230 (54.9)
 Previous 141 (14.5) 192 (12.7) 56 (13.4)
 Current 338 (34.7) 438 (28.9) 133 (31.7)
ITPA rs1127354, CC, n (%) 818 (83.6) 1338 (88.1) 372 (88.6) 0.0020f
ITPA rs7270101, AA, n (%) 793 (81.1) 1254 (82.6) 342 (81.4) 0.6563f
Mean ALT, IU/L ± SD 104.1 ± 103.5 83.4 ± 79.2 72.9 ± 63.8 <0.0001e
Mean ALT ratio ± SDc 2.28 ± 2.07 1.88 ± 1.55 1.65 ± 1.31 <0.0001e
 G1 (n = 1671) 2.09 ± 1.94 1.77 ± 1.38 1.63 ± 1.30 0.0007e
 G2 (n = 312) 2.42 ± 2.58 1.96 ± 1.96 1.21 ± 0.829 0.0061e
 G3 (n = 565) 2.80 ± 2.15 2.32 ± 1.91 2.05 ± 1.62 <0.0001e
 G4 (n = 247) 2.00 ± 1.75 1.66 ± 1.11 1.65 ± 1.09 0.3885e
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ALT alanine transaminase, IL28B interleukin-28B, ITPA inosine triphosphate pyrophosphatase
a Ethnic origin was selected from a drop-down menu in the CSR; “Other” may include patients who are Hispanic, Latino, or identified themselves as Mixed Race
b Percentages calculated for patients with available data only
c ALT ratio is ALT divided by upper limit of normal range
d Includes HCV RNA categories reported as ≤800,000 or >800,000 IU/mL
e Jonckheere-Terpstra Test for a trend of a continuous variable across the three IL28B genotype categories
f Cochran-Armitage Trend Test for a trend in binomial proportions across the three IL28B genotype categories
g Pearson Chi square test
Table 1 continued
IL28B rs12979860 genotype
CC (n = 978) CT (n = 1518) TT (n = 420) P valuee
Mean HCV RNA, log10 IU/mL ± SD 5.94 ± 0.99 5.83 ± 0.81 5.68 ± 0.83 <0.0001e
HCV RNA > 800,000 IU/mL, n (%)bd 607/959 (63.3) 764/1498 (51.0) 179/416 (43.0) <0.0001f
 G1 320/495 (64.6) 493/921 (53.5) 116/268 (43.3) <0.0001f
 G2 81/124 (65.3) 80/157 (51.0) 23/37 (62.2) 0.1853
 G3 152/231 (65.8) 131/276 (47.5) 22/65 (33.8) <0.0001
 G4 44/92 (47.8) 53/128 (41.4) 14/39 (35.9) 0.1792
Assessment of cirrhosis, n (%) 0.0723g
 Biopsy 295 (30.2) 419 (27.6) 114 (27.1)
 Noninvasive 646 (66.0) 1046 (68.9) 289 (68.8)
 Both 37 (3.8) 46 (3.0) 12 (2.9)
 None 1 (0.1) 7 (0.5) 5 (1.2)
Fibrosis stage (biopsy or noninvasive), n (%)
 Assessment made 976 (99.8) 1511 (99.5) 415 (98.8)
 Cirrhosis/transition to cirrhosisb 248 (25.4) 390 (25.8) 119 (28.7) 0.2702f
 No cirrhosisb 728 (74.6) 1121 (74.2) 296 (71.3)
 Missing 2 (0.2) 7 (0.5) 5 (1.2)
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and also included relatively small numbers of patients 
(Falleti et  al. 2011; Fabris et  al. 2011; Di Marco et  al. 
2012).
There is also evidence that contradicts the results of 
the present study: analyses in G1 patients have reported 
that a CC genotype is associated with a higher prevalence 
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Fig. 3 The association between IL28B rs12979860 genotype and liver fibrosis by HCV genotype overall (a), in Caucasian patients with HCV G1 infec-
tion (b), and in European Caucasian patients with HCV G1 infection (c). Significant associations were found between IL28B rs12979860 genotype 
and liver fibrosis in patients with HCV G1 infection (p = 0.0018) (a), in Caucasian treatment-naive patients with HCV G1 infection (p = 0.0010) (b), 
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proportions across the three IL28B genotypes
Page 8 of 13Mangia et al. SpringerPlus  (2016) 5:1990 
of cirrhosis/transition to cirrhosis (Abe et al. 2010), and 
that there is no relationship between IL28B and fibrosis 
stage (D’Ambrosio et  al. 2014; Bochud et  al. 2012). The 
studies by D’Ambrosio et  al. and Abe et  al. measured 
fibrosis by biopsy; however, they included relatively small 
numbers of patients (D’Ambrosio et  al. 2014; Abe et  al. 
2010). While the study by Bochud et al. (2012) included 
a similar number (n  =  919) of Caucasian G1-infected, 
treatment-naive patients, the median duration of HCV 
infection was longer (21 vs ~14 years), and more patients 
had HIV–HCV co-infection (5 vs 3.5%). Two further 
studies found no association between rs12979860 geno-
type and fibrosis stage (Noureddin et al. 2013; Marabita 
et al. 2011).
Associations between IL28B genotype and liver fibrosis 
were restricted to HCV G1 infection in the present study. 
When the data were analysed by geographic region, the 
association between IL28B genotype and fibrosis status 
remained statistically significant in the large subgroup of 
European Caucasian patients with G1 infection but was 
not statistically significant in other populations. The lack 
of a relationship in the smaller subgroup of Asian, Latin 
American and Middle Eastern patients with G1 infection 
may simply be due to the smaller sample size, or may be 
due to factors related to ethnicity that were not measured 
in this analysis. Interestingly there was also a significant 
association between IL28B genotype and APRI score and 
FIB-4 score in the overall population and in patients with 
G2 and G3 infection, but not in those with G1 infection. 
Strong conclusions cannot be drawn regarding the over-
all association between IL28B genotype and fibrosis sta-
tus, as significant associations between C allele frequency 
and cirrhosis/transition to cirrhosis have been reported 
previously (Bochud et al. 2012; Rembeck et al. 2012).
The primary immune response to HCV infection is 
mediated predominantly through IFN-λ cytokines and 
may be influenced by IL28B genotype (Thomas et  al. 
2012; Watanabe et al. 2013). Patients with a “favourable” 
rs12979860 CC genotype are more likely to experience 
spontaneous viral clearance and respond to IFN-based 
therapy (Thomas et al. 2009; Ge et al. 2009), while those 
with the T allele may be at increased risk of HCV-related 
HCC (Zhang et  al. 2016). Interestingly, there is a well-
established association between this “favourable” geno-
type for viral clearance (CC), and increased markers of 
intra-hepatic inflammatory response to HCV infection 
(Noureddin et al. 2013; D’Ambrosio et al. 2014; Abe et al. 
2010; Bochud et al. 2012; Rembeck et al. 2012). The pres-
ence of significantly higher necro-inflammatory activ-
ity and serum ALT levels in patients with CC genotypes 
has been interpreted as an indication of an enhanced 
immune response in patients with CC genotypes as com-
pared with non-CC genotypes (Noureddin et  al. 2013; 
D’Ambrosio et  al. 2014; Rembeck et  al. 2012). A more 
vigorous immune response would be expected to lead to 
more rapid fibrosis progression over time in patients who 
do not experience spontaneous viral clearance. How-
ever, an association with liver fibrosis stage and IL28B 
genotype is less well established (Noureddin et al. 2013; 
D’Ambrosio et  al. 2014; Abe et  al. 2010; Bochud et  al. 
2012; Rembeck et al. 2012). In the current study, the CC 
genotype was associated with higher ALT ratios and a 
lower prevalence of cirrhosis/transition to cirrhosis in 
patients with HCV G1 infection. These results support 
the interpretation that the “favourable” CC genotype 
is associated with a more vigorous antiviral immune 
response but not with higher incidence of fibrosis. Unfor-
tunately, inflammatory grade was not available for many 
patients, which limits the strength of this conclusion.
Recently, it has been shown that different combinations 
of IL28B genotype and toll-like receptor-2 (TLR-2) vari-
ants are associated with different manifestations of HCV-
related liver disease and lymphoproliferative diseases 
(De Re et al. 2016). The IL28B CC genotype exerts a pro-
tective effect on CHC and the development of cirrhosis 
and HCC, while the TLR-2 del/del genotype was associ-
ated with an increased risk of HCC. In combination, the 
presence of one or more TLR-2 del alleles abolished the 
Table 2 Association between  liver fibrosis and  IL28B 
rs12979860 genotype in  patients with  HCV G1 infection, 
by region of enrolment
ND no data available
a Cochran-Armitage trend test for a trend in binomial proportions across the 
three IL28B genotype categories
Patients, n (%) IL28B rs12979860 genotype
CC TC TT p valuea
Asia (n = 25)
 Cirrhosis/transition to 
cirrhosis
8 (50.0) 5 (55.6) ND
 No cirrhosis 8 (50.0) 4 (52.3) ND 0.7896
European (n = 1245)
 Cirrhosis/transition to 
cirrhosis
78 (20.2) 168 (24.8) 57 (31.7)
 No cirrhosis 309 (79.8) 510 (75.2) 123 (68.3) 0.0030
Latin America (n = 137)
 Cirrhosis/transition to 
cirrhosis
9 (29.0) 25 (33.8) 10 (31.3)
 No cirrhosis 22 (71.0) 49 (66.2) 22 (68.8) 0.8547
Middle East (n = 289)
 Cirrhosis/transition to 
cirrhosis
16 (24.6) 57 (34.1) 20 (35.1)
 No cirrhosis 49 (75.4) 110 (65.9) 37 (64.9) 0.2022
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Odds ratio (95% CI) P-value
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Fig. 4 Multiple logistic regression analysis for cirrhosis or transition to cirrhosis in all patients (a), all patients with HCV G1 infection (b), and all Euro-
pean Caucasian patients with HCV G1 infection (c). AST aspartate transaminase; MLR multiple logistic regression
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protective effect of the CC genotype. These data suggest 
that IL28B and TLR-2 are functionally interconnected in 
HCV disease-specific phenomena.
Baseline factors predictive of cirrhosis/transition to cir-
rhosis are similar to those reported elsewhere (Noured-
din et  al. 2013; Falleti et  al. 2011; Bochud et  al. 2012; 
Rueger et al. 2015; Wright et al. 2003). It should be noted 
that attendance at a clinic in Asia (vs Europe) was sig-
nificantly associated with cirrhosis/transition to cirrhosis 
in G1 patients, which seems counterintuitive given that 
the CC genotype was more prevalent in Asian patients. 
However, this result may be explained by the greater pro-
portion of Asian than European patients with cirrhosis at 
baseline (~53 vs ~25%).
Overall, the Gen-C study supports previously pub-
lished frequency distributions of IL28B genotypes. The 
CC genotype was less common in G1 and G4 than G2 
and G3 patients, and the proportions of CC patients in 
each HCV genotype agreed with previous estimates (De 
Nicola et al. 2012; Falleti et al. 2011; Bochud et al. 2012; 
Mottola et  al. 2015). The geographic distribution of 
rs12979860 genotypes also agrees with previous reports, 
with the highest prevalence of the C allele in Asia, and 
the highest prevalence of the TT genotype in Latin 
America (Thomas et al. 2009; Ge et al. 2009). Finally, eth-
nic associations with s12979860 genotypes agree with 
previous reports, with the lowest prevalence of the C 
allele in Black patients, and the highest in Asian patients 
(Thomas et al. 2009; Ge et al. 2009).
Limitations include the small amount of METAVIR 
data collected, which tempers conclusions regarding 
IL28B genotype, inflammatory grade and fibrosis stage. 
Rapid fibrosis progression is associated with factors other 
than IL28B genotype, such as alcohol consumption, liver 
disease other than CHC, HIV–HCV co-infection and 
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Fig. 5 Distribution of IL28B rs12979860 genotype according to HCV 
genotype. The distribution of IL28B rs12979860 genotype varied sig-
nificantly by HCV genotype (a), region of enrolment (b), and ethnicity 
(c). p < 0.0001a for the association between HCV genotype and IL28B 
rs12979860 genotype, p < 0.0001a for the association between geo-
graphic region and IL28B rs12979860 genotype, and p < 0.0001a for 
the association between ethnicity and IL28B rs12979860 genotype. 
aPearson’s Chi square test
Table 3 Distribution of  IL28B rs12979860 genotype 
by region of enrolment and HCV RNA genotype
a Pearson’s Chi square test for differences in IL28B rs12979860 genotype by 
variables
HCV genotype IL28B rs12979860 genotype p valuea
CC CT TT
G1 (n = 1702)
 Asia (n = 25) 16 (64.0) 9 (36.0) 0 (0.0)
 Europe (n = 1251) 388 (31.0) 680 (54.4) 183 (14.6)
 Middle East (n = 289) 65 (22.5) 167 (57.8) 57 (19.7)
 Latin America (n = 137) 31 (22.6) 74 (54.0) 32 (23.4)
 Total (n = 1702) 500 (29.4) 930 (54.6) 272 (16.0) <0.0001
G2 (n = 323)
 Asia (n = 6) 4 (66.7) 2 (33.3) 0 (0.0)
 Europe (n = 291) 111 (38.1) 144 (49.5) 36 (12.4)
 Middle East (n = 19) 7 (36.8) 12 (63.2) 0 (0.0)
 Latin America (n = 7) 4 (57.1) 2 (28.6) 1 (14.3)
 Total (n = 323) 126 (39.0) 160 (49.5) 37 (11.5) 0.3572
G3 (n = 574)
 Asia (n = 105) 45 (42.9) 52 (49.5) 8 (7.6)
 Europe (n = 432) 177 (41.0) 200 (46.3) 55 (12.7)
 Middle East (n = 30) 8 (26.7) 20 (66.7) 2 (6.7)
 Latin America (n = 7) 2 (28.6) 5 (71.4) 0 (0.0)
 Total (n = 574) 232 (40.4) 277 (48.3) 65 (11.3) 0.2041
G4 (n = 260)
 Asia (n = 0) 0 0 0
 Europe (n = 128) 37 (28.9) 64 (50.0) 27 (21.1)
 Middle East (n = 127) 53 (41.7) 62 (48.8) 12 (9.4)
 Latin America (n = 5) 2 (40.0) 3 (60.0) 0 (0.0)
 Total (n = 260) 92 (35.4) 129 (49.6) 39 (15.0) 0.0467
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glucose intolerance, which, notwithstanding our MLR 
analysis, could have confounded the results.
 In summary, an increasing number of rs12979860 T 
alleles is associated with an increased prevalence of cir-
rhosis/transition to cirrhosis in treatment-naïve patients 
with HCV G1 infection. When the G1 population was 
categorized geographically, this association was evi-
dent in the large subgroup of European Caucasians with 
HCV G1 infection but not in the smaller subgroups of 
G1-infected patients from Asia, Latin America or the 
Middle East. Thus, the presence of the T allele may be 
used to prioritize treatment for G1 patients who are at 
increased risk of progressing to cirrhosis.
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mental Hospital IEC, Nabatieh; Hotel Dieu De France IEC, Ashrafieh; Haykel 
Hospital IEC, Tripoli; Sahel General Hospital IEC, Dahieh; Rafic Hariri University 
Hospital IRB, Beirut; Commission d’Ethique de la Recherche (CER), Baabda.
Lithuania: State Medicines Control Agency/Lithuanian Bioethics Commit-
tee, Vilnius.
Macedonia: Eticka Komisija, Ministerstvo za zdravstvo, Skopje.
Mexico: Comité de Investigación para estudios en Humanos, Mexico City; 
Comision Nacional de Investigación Científica, Piso.
Oman: College of Medicine and Health Sciences, Sultanate of Oman
Pakistan: Allied Med Ethics, Shan Hospital, Karachi; Ethics Review Com-
mittee, South City Hospital, Karachi; Institutional Review Board, Lahore General 
Hospital, Post Graduate Medical Institute, Lahore; Institutional Review Board, 
Shaikh Zayed Hospital, Lahore; Ethics Review Committee, Chaudhry Hospital, 
Gujranwala; Institutional Review Board/Ethics Committee, Doctors Hospital 
and Medical Center, Lahore; Secretariat Ethical Review Committee (ERC), 
Faisalabad.
Peru: Comité de Etica del Hospital Rebagliati, Lima; Comité de Etica en 
Investigacion del Hospital Nacional Guillermo Almenara Irigoyen, Lima;
Portugal: Comissão de Ética para a Saúde do Centro Hospitalar do Baixo 
Vouga, EPE, Aveiro; Comissão de Ética para a Saúde do Hospital Professor Dr. 
Fernando da Fonseca, EPE, Amadora; Comissão de Ética para a Saúde do Hos-
pital de Faro, EPE, Faro; Comissão de Ética para a Saúde do Centro Hospitalar 
do Porto, EPE, Porto; Comissão de Ética para a Saúde do Centro Hospitalar de 
Lisboa Ocidental, EPE, Lisboa; Comissão de Ética para a Saúde do Hospital Gar-
cia de Orta, EPE, Almada; Comissão de Ética para a Saúde do Centro Hospitalar 
Lisboa Norte, EPE, Lisboa; Comissão de Ética para a Saúde do Hospital de São 
João, EPE, Porto.
Qatar: Medical Research Center at Hamad Medical Corporation, Doha.
Romania: Comisia Naţională de Bioetică a Medicamentului şi a Dispozi-
tivelor Medicale, Bucharest.
Serbia: Ethics Committee Clinical Center of Vojvodina, Novi Sad; Ethics 
Committee Clinical Hospital Center Zvezdara, Belgrade.
Slovakia: Eticka Komisia BSK, Bratislava; Eticka Komisia SZU, Bratislava; 
Eticka Komisia FNsP JA Reimanna, Presov; Eticka Komisia UNM, Martin; Eticka 
Komisia un Bratislava Nemocnica Akad. L. Derera, Bratislava; Eticka Komisia 
FNsP FDR, Banska Bystrica.
Sweden: Regionala Etikprovningsnamnden i Uppsala, Uppsala.
Switzerland: Comitato Etico Cantonale, Bellinzona; Ethikkomission 
Kantonsspital, St Gallen.
Syria: Ministry of Health Syria, Damascus.
Taiwan: China Medical University and Hospital Research Ethics Com-
mittee, Taichung City; Chang Gung Medical Foundation Institutional Review 
Board, Guishan Township, Taoyuan County; National Taiwan University Hospital 
Research Ethics Committee, Taipei City; Kaohsiung Medical University Chung-
Ho Memorial Hospital Institutional Review Board, Kaohsiung City; Institutional 
Review Board, Taipei Veterans General Hospital, Taipei City
Turkey: Ankara Universtiesi Tıp Fakultesi Klinik Arastırmalar Etik Kuurlu, 
Ankara.
UAE: Al Qassimi Clinical Research Center, Sharjah; Medical Research Com-
mittee, Dubai Health authority, Dubai.
Venezuela: Comité de Etica Hospital Dr. Domingo Luciani, Caracas; 
Comité de Ética Hospital Clinico Maracaibo, Maracaibo; Comité de Ética para la 
Investigación Centro Medico Docente La Trinidad, Caracas; Comité de Bioetica 
Centro Médico La Floresta, Caracas; Comité de Bioetica para la Investigación 
Hospital de Clinicas Caracas, Caracas.
Informed consent in studies with human subjects
All procedures followed were in accordance with the ethical standards of the 
responsible committee on human experimentation (institutional and national) 
and with the Helsinki Declaration of 1975, as revised in 2008 and in line with 
the guidelines for good clinical practice set out in the International Confer-
ence on Harmonisation (ICH) Tripartite Guideline. All patients included in the 
study provided written, informed consent.
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